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Summary
MyoD regulates skeletal myogenesis. Since proteins
associated with MyoD exert regulatory functions, their
identification is expected to contribute important in-
sights into the mechanisms governing gene expres-
sion in skeletal muscle. We have found that the RNA
helicases p68/p72 are MyoD-associated proteins and
that the noncoding RNASRA also immunoprecipitates
with MyoD. In vitro and in vivo experiments indicated
that both p68/p72 and SRA are coactivators of MyoD.
RNA interference toward either p68/p72 or SRA pre-
vented proper activation of muscle gene expression
and cell differentiation. Unexpectedly, reducing the
levels of p68/p72 proteins impaired recruitment of the
TATA binding protein TBP; RNA polymerase II; and
the catalytic subunit of the ATPase SWI/SNF complex,
Brg-1, andhinderedchromatin remodeling. Thesefind-
ings reveal that p68/p72play a critical role inpromoting
the assembly of proteins required for the formation
*Correspondence: sartorev@mail.nih.govof the transcription initiation complex and chromatin
remodeling.
Introduction
The specification of different cell lineages starting from
totipotent stem cells lies at the core of development
and organogenesis. During this process, the genome
of a cell is modified to ensure that stable, if not irrevers-
ible, distinctions are made between genes not to be
expressed from genes whose expression is or will be
required. At the molecular level, these distinctions are
brought about by specific modifications of the chroma-
tin. Indeed, the developmental activation of genes ex-
pressed in highly differentiated cell types is character-
ized by a defined chromatin conformation (Weintraub
and Groudine, 1976) that depends on the interaction of
trans regulatory proteins (transcriptional regulators)
with cis DNA sequences (regulatory regions). DNA bind-
ing of transcriptional regulators is a prerequisite, but it
is insufficient to initiate transcription. To effectively pro-
mote gene activation, transcriptional regulators recruit
proteins that, while per se incapable of recognizing spe-
cific DNA modules, can modify the structure and function
of the chromatin and of the transcriptional regulators
themselves. Thus, gene expression is regulated by both
DNA binding of transcriptional regulators and by the
composition of the associated protein complexes.
MyoD and the related myogenic bHLH proteins spec-
ify and direct differentiation of the skeletal muscle line-
age in mice (Sabourin and Rudnicki, 2000; Buckingham
et al., 2003) by interacting with a specific DNA module,
the E-box, located in the regulatory regions of genes ex-
pressed in skeletal muscle (Lassar et al., 1989, 1991). In
this process, the MEF2 proteins cooperate with the myo-
genic bHLH proteins (Molkentin et al., 1995). The regula-
tion of MyoD activity is complex and only partially under-
stood (Tapscott, 2005; Sartorelli and Caretti, 2005).
While binding of MyoD to its DNA targets is generally fol-
lowed by gene activation, some target genes are bound
and not activated (Ohkawa et al., 2006) or are activated
with different kinetics (Bergstrom et al., 2002; Blais
et al., 2005; Ishibashi et al., 2005; Cao et al., 2006). More-
over, MyoD can repress gene expression (Bergstrom
et al., 2002). Association of MyoD and MEF2 with histone
modifiers and chromatin remodeling complexes is be-
lieved to regulate their transcriptional activity. Interac-
tion of class I and class III histone deacetylases (HDACs)
with MyoD (Mal et al., 2001; Puri et al., 2001; Fulco et al.,
2003) and of class II and class III HDACs with MEF2C
(Zhang et al., 2002; Zhao et al., 2005) may prevent prema-
ture gene activation in undifferentiated myoblasts. More-
over, methylation of specific histone lysine residues at
muscle loci (Zhang et al., 2002; Caretti et al., 2004; Mal
and Harter, 2003) likely reinforces the inhibitory effects
exerted by the HDACs. At the onset of differentiation, the
composition of the protein complexes interacting with
the myogenic bHLH and MEF2 proteins is modified to
accommodate recruitment of the chromatin remodeling
SWI/SNF, p300, and PCAF histone acetyltransferases
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cales and Puri, 2005). Because of the regulatory func-
tions exerted by the proteins associated with MyoD,
the identification and characterization of the individual
components of these protein complexes are expected
to contribute important insights into the mechanisms
governing gene expression in skeletal muscle.
In this study, we report that the RNA helicases p68/
p72 are MyoD-interacting proteins and that the noncod-
ing RNA steroid receptor RNA activator (SRA) can be
coimmunoprecipitated with MyoD. p68/p72 and SRA
coactivate MyoD-dependent transcription and are re-
quired for skeletal muscle cells to properly differentiate.
Unexpectedly, we found that p68/p72 are mechanisti-
cally linked to the productive recruitment of proteins re-
quired for the formation of the transcription initiation
complex, chromatin remodeling, and transcriptional
activation of muscle loci.
Results
MyoD Interacts with p68 and p72, Two Members
of the DEAD-Box Family of RNA Helicases
To facilitate the purification and identification of proteins
that associate with MyoD, HeLa cells were transduced
with the pOZ retrovirus expressing a bicistronic mRNA
encoding Flag and HA epitope-tagged MyoD linked to
the ILR2 a subunit surface marker via an internal ribo-
somal entry site. The transduced cells were purified by
repeated cycles of affinity cell sorting on magnetic
beads coated with an IL2a receptor antibody and uni-
form positive reactivity of the cell population to both
MyoD and IL2a confirmed by immunofluorescence mi-
croscopy and FACS analysis. Because we employed
a low viral titer, the level of MyoD protein expressed in
HeLa cells was comparable to that detected in C2C12
skeletal muscle cells (data not shown). Nuclear extracts
were prepared and purified by affinity chromatography
on anti-Flag antibody-conjugated agarose. The bound
material was first eluted with the epitope Flag peptide
under native conditions and was subsequently repuri-
fied on a second anti-HA antibody-conjugated agarose.
Polypetides were eluted from the resin by denaturing
with SDS and heat. As a control, the same purification
scheme was performed with nuclear extracts obtained
from nontransduced HeLa cells.
Several polypeptides copurified specifically with the
epitope-tagged MyoD (e-MyoD) (Figure 1A, compare
lanes 3 and 5), and their identity was determined by
mass spectrometry. Numerous MS/MS spectra were
assigned to peptides belonging to proteins known to in-
teract with MyoD, such as E proteins (Murre et al., 1989),
class I HDACs (Mal et al., 2001; Puri et al., 2001), and the
corepressors NcoR/SMRT (Bailey et al., 1999) (data not
shown and Figure S1A; see the Supplemental Data avail-
able with this article online). Another set of MS/MS spec-
tra corresponded to peptides of proteins not previously
reported to interact with MyoD. Among these, we fo-
cused on the set of peptides whose sequences are
shown in Figure 1B and that were assigned to the two
RNA helicases, p68 and p72, with high sequence homol-
ogy (Figure 1C). We confirmed that the peptides identi-
fied by mass spectrometry corresponded to the p68
protein by immunoblotting (Figure 1D). The strength ofthe interaction of p68 with MyoD was comparable to
that of HDAC3 and NcoR, two other proteins identified
by mass spectrometry as MyoD-associated factors (Fig-
ure S1A). Recognizing the physiological limitations of
the cellular system employed to isolate MyoD-asso-
ciated factors, we evaluated whether p68/p72 may inter-
act with MyoD in extracts of skeletal muscle cells.
Endogenous MyoD immunoprecipitated from nuclear
extracts of differentiated C2C12 muscle cells interacted
with endogenous p68 (Figure 1E) and p72 (data not
shown). The results reported in this paragraph suggest
that p68/p72 are bona fide MyoD-associated factors.
The p68 and p72 Proteins and the Noncoding RNA
Steroid Receptor Activator SRA Are Transcriptional
Coactivators of MyoD
The mass spectrometry protocol employed to identify
MyoD-associated factors is not suited to reveal the
presence of nucleic acids. p68/p72 are RNA binding pro-
teins that interact with a regulatory noncoding RNA, the
SRA (Watanabe et al., 2001). Before initiating an investi-
gation into the role of p68/p72 in myogenesis, we wished
to determine whether SRA might be associated with
MyoD and/or p68. Expression vectors for either Flag-
MyoD or Flag-p68 were transfected in 293 T cells, and
the cell extracts were immunoprecipitated with an anti-
Flag antibody-conjugated agarose or control immuno-
globulin. The immunoprecipitated material was treated
with DNaseI to eliminate potentially present genomic
DNA and was subsequently subjected to a reverse tran-
scription reaction. The cDNA was PCR amplified with
primers specific for either SRA or, as a negative control,
tubulin. The results shown in Figure 2A and Figure S1D
indicate that p68 and MyoD coimmunoprecipitated
RNAs corresponding to SRA sequences. Moreover, in
extracts derived from HeLa-Flag-MyoD cells, but not
control HeLa cells, SRA was immunoprecipitated by
anti-Flag antibodies (Figure S1B). Similar experiments
conducted with differentiated myotubes revealed that
SRA is associated with endogenous p68 or MyoD in
skeletal muscle cells (Figure 2B). Reactions in which
the reverse transcription step was omitted did not give
signals above background (data not shown). The asso-
ciation of MyoD and p68 is unlikely to be mediated by
SRA since treatment with RNase did not prevent the
interaction of the two proteins in nuclear extracts of dif-
ferentiating C2C12 cells (Figure S1E). Real-time PCR
(RT-PCR) performed on RNase-treated nuclear extracts
failed to amplify transcripts corresponding to SRA, indi-
cating that RNase treatment was successful (data not
shown). The observation that MyoD, p68/p72, and SRA
have the potential to form a protein-RNA complex
prompted us to test for their functional relevance to
muscle gene transcription. To this end, the muscle-spe-
cific creatine kinase enhancer linked to the luciferase
gene (MCK-luc) construct was transfected in NIH3T3
murine fibroblasts. Transfection of either individual or
pairwise combinations of p68, p72, and SRA expression
vectors had no effect on MCK-luc in the absence of
MyoD (Figure 2C). Conversely, MyoD-dependent trans-
activation of MCK-luc was increased, in a dose-depen-
dent manner, by coexpression of either p68 or p72.
SRA, either alone or, more effectively, in combination
with p68 or p72, also augmented MyoD-dependent
RNA Helicases and Noncoding RNA Control Myogenesis
549Figure 1. Purification and Identification of p68/p72 as MyoD-Associated Proteins
(A) Nuclear extracts were prepared from either mock-transduced control (lane 3) or MyoD-expressing HeLa cells (lane 5) and purified by affinity
chromatography as described by Nakatani and Ogryzko (2003). Proteins were resolved by SDS-PAGE, and the gel was stained with Simply Blue
(Invitrogen). The arrowhead points at bands later identified as p68/p72, and the arrow points to epitope-tagged MyoD (e-MyoD).
(B) Peptide sequences identified by mass spectrometry and corresponding to human RNA helicase p68/p72 proteins.
(C) Alignment of human p68/p72 proteins. The light-blue boxes identify p68-specific peptide sequences, the pink box indicates a p72-specific
peptide, and the green boxes encompass common p68/p72 peptide sequences.
(D) Nuclear extracts from either mock-infected control (lane 3) or MyoD-expressing HeLa cells (lane 4) were immunopurified on anti-Flag anti-
body-conjugated agarose, and the materials were resolved by SDS-PAGE and immunoblotted with p68 and MyoD antibodies. A total of 20%
of the total protein inputs for control (lane 1) and MyoD-expressing (lane 2) HeLa extracts.
(E) Nuclear extracts of C2C12-differentiated muscle cells were immunopurified with either control IgG (lane 2) or MyoD antibody (lane 3), and the
materials were resolved by SDS-PAGE and immunoblotted with a p68 antibody. The asterisk indicates a band often observed to react with p68
antibody and, most likely, generated by partial proteolysis of the p68 protein. Lane 1 shows 10% of the protein input employed in lanes 2 and 3.transactivation. NIH3T3 cells express p68 (Figure S2A)
to assist SRA-mediated coactivation of MyoD in the ab-
sence of transfected p68 (Figure 2C). The strongest ac-
tivation of MCK-luc was observed when p68, p72, and
SRA were simultaneously cotransfected with MyoD.
An expression vector bearing a substitution of a single
amino acid of p68 (K144R) located in the ATP binding
domain, which is also conserved in the ATP binding do-
main of p72 (Lamm et al., 1996) and inactivates p68’s
RNA helicase activity (Endoh et al., 1999), continued to
coactivate MyoD-dependent transcription, either in the
absence or presence of transfected SRA (Figure 2D), in-
dicating that the helicase activity of p68 is dispensable
to regulate MCK-luc transcription. SRA expressed in anti-
sense (30-50) orientation failed to coactivate MyoD (Fig-
ure S2B). As reported for the bHLH E47 protein (Lanz
et al., 1999), SRA was also incapable of coactivatingtranscription mediated by the bHLH E2-5 (ITF-1), a
protein related to, but distinct from, E47 (Figure S2C).
Recently, Drosophila p68 has been reported to regulate
transcriptional deactivation by promoting RNA release
from chromatin (Buszczak and Spradling, 2006). These
findings raise the possibility that the effects exerted by
p68 on MyoD-dependent transcription may be indirect,
i.e., p68 may deactivate transcription of a MyoD inhibitor
and, consequently, favor MyoD activity. To rule out both
this and other possible indirect effects of p68/p72 and
SRA on MyoD-dependent transcription, we evaluated
their ability to activate muscle gene transcription in a
MyoD-dependent in vitro transcription system based
on a chromatin-reconstituted template. A DNA template
encompassing four copies of a MyoD binding site
derived from the MCK enhancer linked to the MCK pro-
moter (4R-MCK) was incorporated into nucleosomal
Developmental Cell
550Figure 2. p68/p72 and the Noncoding RNA Steroid Receptor Activator, SRA, Coactivate MyoD-Dependent Transcription
(A) 293 T cells were transfected with the indicated Flag-tagged expression vectors, and cell extracts were prepared and immunopurified on anti-
Flag antibody-conjugated agarose. The immunopurified materials were first treated with DNaseI and then subjected to RT-PCR with specific
primers for SRA. As control, the same materials were also amplified with specific primers for tubulin transcripts. The values obtained with
RT-PCR analysis for SRA amplifications were normalized to the values obtained for tubulin amplifications. Error bars represent standard devi-
ations.
(B) Experiments were conducted as described in (A), except that cell extracts from C2C12 skeletal muscle cells immunopurified with either p68 or
MyoD antibodies were employed. Error bars represent standard deviations.
(C) NIH3T3 fibroblasts were transfected with the MCK-luc reporter and expression vectors for MyoD, p68, p72, and SRA in different combina-
tions. Two different concentrations (50 ng, +; 250 ng, ++) of p68/p72 plasmids were employed, while concentrations of the MyoD (20 ng) and SRA
(50 ng) plasmids were kept constant. A luciferase assay was conducted on cell extracts lysed 48 hr after transfection. A total of 50 ng of a CMV-
lacZ-expressing vector was cotransfected, and a b–gal assay was performed to correct for transfection efficiency. Experiments were done with
triplicate samples and were repeated 4–5 times. Error bars represent standard deviations.
(D) Expression vectors for MyoD, wild-type (wt) p68, and helicase-deficient p68 (p68 K144R) were transfected in NIH3T3 cells in the presence of
the MCK-luc reporter, and luciferase activity was determined as described in (C). Error bars represent standard deviations.
(E) Recombinant proteins used for the in vitro studies, except for His-p300, which was purified by using Ni2+-NTA resin, were expressed in
baculovirus-infected Sf-9 cells and purified by anti-Flag affinity chromatography. The homogeneity of the purified proteins was confirmed by
Coomassie blue staining after SDS-PAGE. SRA was transcribed as reported in Experimental Procedures, and an aliquot was analyzed on
a 1% agarose gel after ethidium bromide staining.
(F) Flag-MyoDwE12 transcription from the nucleosomal 4R-MCK template was examined in the absence or presence of Flag-p68, Flag-p72, and
SRA. Inclusion of Flag-p68, Flag-p72, and SRA increased MyoDwE12-mediated transcription byw5-fold (compare lanes 3 and 4). SRA alone
increased Flag-MyoDwE12 transcription byw4-fold (compare lanes 5 and 6). Flag-p68 increased MyoDwE12 transcription byw2-fold (com-
pare lanes 5 and 7). His-p300, Flag-PCAF, and acetyl-CoA were present in every reaction. Transcription from the pG1 template served as an
internal control. Quantification of the in vitro transcription reactions was performed by scanning the gel autoradiogram with the NIH ImageJ
software.
(G) C3H10T1/2 mouse embryonic fibroblasts were transfected with different combinations of MyoD, Myc-p68, and SRA expression vectors,
and their myogenic conversion was scored by immunostaining with myosin heavy chain (MHC, green) antibodies after culturing them for
72 hr in differentiation medium. Reactivity with the myc-epitope of the Myc-p68 protein is indicated in red, and DAPI (blue) marks the cell
nuclei.
(H) The levels of MHC transcripts were investigated by RT-PCR, expression of Flag-MyoD and Myc-p68 in transfected C3H10T1/2 cells was
evaluated by immunoblotting, and expression of SRA in transfected C3H10T1/2 cells was evaluated by RT-PCR. Tubulin protein and GAPDH
RNA served as loading controls.
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551arrays, and baculovirus-produced and -purified MyoD
fused to its physiological protein partner E12 (My-
oDwE12), p68/p72 proteins, and in vitro-transcribed
SRA (Figure 2E) were assayed in a transcription reaction.
Formation of the nucleosomal arrays was confirmed
by micrococcal nuclease digestion (data not shown).
The acetyltransferase p300 and PCAF proteins were in-
cluded in the transcription reaction, as they have been
shown to be required for MyoDwE12-dependent trans-
activation (Dilworth et al., 2004). The pG1 template, con-
taining the b-globin gene promoter, was employed as an
internal control. Positioning of nucleosomes on the 4R-
MCK template established a transcriptionally repressed
state on the promoter region since no transcription was
observed from the nuclear extract in the absence of
MyoDwE12 protein (Figure 2F, lanes 1 and 2). While
the addition of MyoDwE12 (in the presence of a nuclear
extract) was sufficient to overcome the repressive ef-
fects on transcription (lane 3), the addition of Flag-p68,
Flag-p72, and SRA resulted in a further 5-fold increase
in transactivation (compare lanes 3 and 4). SRA on its
own was able to increase MyoDwE12-dependent trans-
activation w4-fold (lane 6), while p68 demonstrated a
weaker, but very reproducible, increase in transactiva-
tion in the presence of MyoDwE12, alone or in combina-
tion with SRA (lanes 7 and 8). The limited increase in
transactivation observed in the presence of p68 may
be due to the large amount of the RNA helicases (both
p68 and p72) present in the HeLa nuclear extract em-
ployed in the transcription reaction (data not shown).
Thus, the in vitro transcription system confirms that
SRA is a coactivator of MyoDwE12, and it lends further
support to the above-mentioned data that demonstrate
that p68/p72 facilitate transactivation by MyoD.
Finally, we assessed the abilities of p68 and SRA to
coactivate MyoD in a biologically relevant assay. Ex-
pression of MyoD can convert C3H10T1/2 mouse embry-
onic fibroblasts into skeletal muscle (Tapscott, 2005).
C3H10T1/2 cells were transfected with different combi-
nations of MyoD, p68, and SRA expression vectors,
and their myogenic conversion was scored by immunos-
taining with myosin heavy chain (MHC) antibodies and
by evaluating MHC gene expression by RT-PCR. As
expected, neither p68 nor SRA induced myogenic con-
version (data not shown); however, MyoD was effective
in conferring the skeletal myogenic phenotype to
C3H10T1/2 cells, as indicated by MHC+ reactivity and
cell morphology. Coexpression of either SRA, p68, or,
more effectively, p68 and SRA increased the ability of
MyoD to convert C3H10T1/2 cells to muscle (Figures
2G and 2H). Cells expressing p68 and MHC were also al-
ways MyoD positive (data not shown). The possibility
that transfected p68 and/or SRA transactivated the plas-
mid expressing exogenous MyoD was ruled out (Fig-
ure 2H). Thus, p68 and SRA can effectively increase
MyoD-induced conversion of mouse fibroblasts to skel-
etal muscle cells.
p68 Is Recruited at the Chromatin Regulatory
Regions of Actively Transcribed Muscle Loci
To evaluate whether the location of endogenous p68
protein is consistent with its ability to influence muscle
gene expression, we used chromatin immunoprecipita-
tion (ChIP) to assay for its presence at two regulatory re-gions of muscle-specific genes. Chromatin obtained
from either undifferentiated myoblasts or differentiated
myotubes was immunoprecipitated with an anti-p68 an-
tibody or control immunoglobulin, and the immunopre-
cipitated DNA was analyzed by RT-PCR with primers
amplifying regulatory regions of the MHCIIb and MCK
genes. We were not able to obtain a p72 antibody suit-
able for ChIP and have limited our analysis to p68.
Despite being expressed at comparable levels in undif-
ferentiated and differentiated skeletal muscle cells (Fig-
ure 3A), p68 was found at muscle regulatory regions
exclusively in differentiated myotubes (Figure 3B, MT),
when both the MHCIIb and MCK are transcribed (Fig-
ure 3C). p68 did not associate with the promoter of the
b-globin gene, which is not expressed in skeletal muscle
cells. On the contrary, p68 was recruited at the promoter
of the estrogen-responsive pS2 gene in MCF7 cells
treated with estradiol (Metivier et al., 2003) with an effi-
ciency comparable to that observed for muscle regula-
tory regions (Figure S2D). p68 could not be detected at
the GAPDH promoter either in myoblast or myotubes
(Figure S2E). Collectively, these findings indicate that
p68 is not a general transcriptional coactivator, but
that, rather, it is engaged at regulatory regions of specific
genes where its presence is associated with gene activa-
tion. To investigate whether p68 was confined to the pro-
moter regions or, after initial promoter recruitment, might
become part of the elongation complex, we performed
ChIP experiments with antibodies against p68, RNA
polymerase II (Pol II), MyoD, or control IgG. The immuno-
precipitated chromatin was amplified with primers span-
ning different regions of the MHCIIb gene corresponding
to the promoter, initial coding regions, and coding re-
gions located 19 Kb from the promoter (Figure 3D). While
MyoD, p68, and Pol II could be detected at the MHCIIb
promoter, only Pol II was present at the MHCIIb coding
regions. These results indicate that engagement of p68
is limited to the regulatory chromatin regions of tran-
scribed genes.
p68, p72, and SRA Are Required for Proper Muscle
Gene Expression and Skeletal Muscle Differentiation
We reduced the p68/p72 protein levels by RNA interfer-
ence in C2C12 cells and mouse primary skeletal myo-
blasts to evaluate their role in regulating muscle gene
expression and cell differentiation. Muscle cells were
transduced with either a control or a retrovirus express-
ing a short hairpin (sh) RNA targeting both p68 and p72
RNAs. Cells receiving the shRNA p68/p72 retrovirus had
reduced levels of p68/p72 proteins of MHC and failed to
form multinucleated myotubes (Figures 4A, 4B, 4E, and
4F). Several experiments were performed to address the
specificity of the shRNA p68/p72-induced phenotype.
C2C12 cells transfected with chemically modified short
interfering (si) double-stranded RNAs, which do not
activate the PKR interferon response pathway, cor-
responding to p68/p72 mRNA sequences also failed
to appropriately differentiate (Figure S3A). On the con-
trary, transfection of siRNAs with ‘‘scrambled’’ p68/p72
sequences did not appreciably affect cell differentia-
tion (Figure S3A). Moreover, the differentiation defects
induced by siRNA p68/p72 in C2C12 were rescued
by retroviral expression of a p68 bearing three silent
third-codon point mutations within the region targeted
Developmental Cell
552Figure 3. p68 Is Recruited at the Regulatory Regions of Transcriptionally Active Muscle Loci
(A) Immunoblotting of cell extracts from undifferentiated (MB, myoblasts) and differentiated (MT, myotubes) C2C12 cells with p68 and tubulin
antibodies.
(B) ChIP assay with chromatin from C2C12 MB or MT and p68 antibodies or control IgG. The precipitated DNA was amplified by RT-PCR with
primers for the MHCIIb promoter, MCK enhancer, and b-globin promoter. Error bars represent standard deviations.
(C) RT-PCR of MHCIIb, MCK, and GAPDH transcripts in undifferentiated (MB) or differentiated (MT) C2C12 cells.
(D) ChIP assay of chromatin from differentiated C2C12 cells and antibodies against MyoD, p68, Pol II, and control IgG. Regions corresponding to
the promoter (region A), initial coding regions (regions B and C), and coding regions located 19 Kb from the MHCIIb promoter (region D) were
amplified by RT-PCR. Error bars represent standard deviations.by the siRNA p68/72 that render it refractory to RNA in-
terference (Figures S3B and S3C). The inability of shRNA
p68/p72 cells to exit the cell cycle and differentiate coin-
cided with a sustained ability to incorporate BrdU; fail-
ure to downregulate cyclins D1, E2, A2, B1, and F; and
elevated E2F activity when cultured in differentiation
medium (Figure S4 and Table S1). To obtain a global
description of the genes regulated by p68/p72 in
skeletal muscle cells, we employed RNAs derived from
shRNA p68/p72 and control C2C12 cells to perform
genome-wide expression profiling. The levels of numer-
ous transcripts, including those corresponding to mus-
cle structural proteins (myosins, actins, troponins), mus-
cle enzymes, and transcriptional regulatory proteins,
were reduced in C2C12 shRNA p68/p72 cultured in
differentiation medium (Table 1, Figure S5, and Expres-
sion Profiling Data at http://pepr.cnmcresearch.org).
Consistent with a role of p68/p72 in coregulating othertranscription factors, non-muscle-specific transcripts
were also affected by p68/p72 (Table 1 and http://
pepr.cnmcresearch.org). Of interest, the transcripts for
two antagonists of the promyogenic Wnt proteins—
secreted Frizzled-related sFRP1 and sFRP2 (Leyns
et al., 1997)—were increased in C2C12 shRNA p68/p72
cultured in growth medium by 3.9- and 9.6-fold, respec-
tively (http://pepr.cnmcresearch.org). Expression of
some of the transcripts identified as being affected by
shRNA p68/p72 in the genome-wide profiling was inde-
pendently evaluated by nonquantitative as well as quan-
titative PCR (Figures 4C, 4D, and 4G), and the results
were found to be concordant with those obtained with
the DNA microarray experiments. Previous work has
identified MEF2A (Bergstrom et al., 2002), pRb (Berg-
strom et al., 2002; Magenta et al., 2003), and follistatin
(Iezzi et al., 2004) as genes regulated by MyoD. Interest-
ingly, expression of MEF2A, pRb, and follistatin was
RNA Helicases and Noncoding RNA Control Myogenesis
553Figure 4. RNA Interference of p68/p72 Impairs Muscle Gene Expression and Skeletal Muscle Differentiation
(A) C2C12 cells transduced with either a control or a retrovirus expressing a short hairpin RNA targeting both p68 and p72 RNAs (shRNA p68/
p72). Cells were grown in differentiation medium for 36 hr. Immunofluorescence was performed with an MHC antibody.
(B) Immunoblot analysis of p68, p72, MHC, and tubulin in control (2) and shRNA p68/p72 (+) C2C12 cells.
(C) RT-PCR analysis of p68, MCK, MHC, SRA, FS (follistatin), and GAPDH transcripts in control (2) and shRNA p68/p72 (+) C2C12 cells.
(D) RT-PCR analysis of MCK, MHC, Tnni2 (troponin I2), TnnT1 (troponin T1), MEF2C, myogenin, MEF2A, FS, and Rb (retinoblastoma) transcripts
in control and shRNA p68/p72 C2C12 cells. Error bars represent standard deviations.
(E) Mouse primary myoblasts were transduced with either control or shRNA p68/p72 retrovirus, were prompted to differentiated for 36 hr, and
were immunostained for MHC.
(F) Immunoblot of p68, MHC, and tubulin of control (2) and shRNA p68/p72 (+) mouse primary myoblasts.
(G) RT-PCR analysis of MCK, MHC, MEF2A, FS, and Rb transcripts in control and shRNA p68/p72 mouse primary myoblasts.
(H) ChIP assay of chromatin from differentiated C2C12 cells and p68 antibody or control IgG. Regulatory regions of the MCK, MEF2A, FS, and Rb
genes were amplified by RT-PCR. Error bars represent standard deviations.
(I) The MCK-luc, myogenin (MG)-luc, 4RE-luc, or empty vector pGL2-luc constructs were transfected in control (C) or in shRNA p68/p72 C2C12 (i).
Cells were cultured in differentiation medium for 36 hr and were processed to detect for luciferase activity. The CMV-lacZ-expressing vector was
cotransfected as an internal control. Error bars represent standard deviations.increased in differentiated myotubes compared to un-
differentiated myoblasts, irrespective of whether p68/
p72 was interfered or not (http://pepr.cnmcresearch.
org). These results were independently confirmed by
quantitative PCR (Figures 4D and 4G). If p68/p72 do
not regulate expression of MEF2A, pRb, and follistatin
genes, it is possible that these proteins may not be re-
cruited at their chromatin regulatory regions. To test this
hypothesis, we performed ChIP experiments and found
that, in contrast to the p68/p72-regulated MCK gene,
p68 could not be detected on the chromatin regions reg-
ulating expression of MEF2A, pRb, and follistatin (Fig-
ure 4H). Muscle-specific regulatory regions comprise
arrays of several DNA modules recognized by differenttranscription factors. While the data obtained with an
in vitro transcription assay data suggest that the p68/
p72 proteins are bona fide coactivators of MyoD-depen-
dent transcription (Figure 2F), we wished to further test
whether they behave in a similar fashion in a cellular con-
text. To this end, control and shRNA p68/p72 C2C12
cells were transfected with two reporter constructs
bearing naturally occurring muscle regulatory regions—
the MCK-luc and the myogenin promoter (MG-luc)—and
an artificial construct—the 4RE-luc—bearing four multi-
merized MyoD binding sites, respectively. The empty
cloning vector (pGL-2-luc) was employed as a negative
control. The variability of transfection efficiency was
corrected by employing a CMV-lacZ vector as an
Developmental Cell
554Table 1. Genes Affected by p68/p72
Nucleotide UniGene Muscle Structural Genes Fold Reduction
NM_008664 Mm.272115 myomesin 2 (Myom2) 27
NM_010855 Mm.297382 myosin, heavy polypeptide 4, skeletal muscle (Myh4) 25
NM_010867 Mm.4103 myomesin 1 (Myom1) 24.3
NM_021503 Mm.141157 myozenin 2 24.2
NM_033268 Mm.37638 actinin alpha 2 23.7
NM_020033 Mm.143737 ankyrin repeat domain 2 (stretch responsive muscle) 23.5
NM_013808 Mm.17235 cysteine and glycine-rich protein 3 22.8
NM_013456 Mm.5316 actinin alpha 3 22.5
NM_009405 Mm.39469 troponin I, skeletal, fast 2 22.5
NM_010861 Mm.1529 myosin, light polypeptide 2, regulatory, cardiac, slow 22.4
NM_010858 Mm.247636 myosin, light polypeptide 4, alkali; atrial, embryonic 22
NM_007617 Mm.3924 caveolin 3 22
NM_011620 Mm.350054 troponin T3, skeletal, fast 22
NM_010858 Mm.247636 myosin light peptide 4 (Myl4) 22
NP_036048 Mm.29733 LIM domain binding 3 21.8
NM_021285 Mm.1000 myosin, light polypeptide 1, alkali; atrial, embryonic 21.8
NM_030679 Mm.340132 myosin, heavy polypeptide 1, skeletal muscle, adult 21.8
NM_016754 Mm.14526 myosin light chain, phosphorylatable (Mylpf) 21.7
NM_009393 Mm.712 troponin C (Tnncc) 21.6
NM_013593 Mm.201606 myoglobin (Mb) 21.6
NM_011618 Mm.358643 troponin T1 (Tnnt1) 21.6
XM_354614 Mm.340090 myosin, heavy polypeptide 3 (Myh3) 21.5
NM_011652 Mm.26579 titin (Ttn) 21.4
Metabolic Processes
NM_009731 Mm.90151 aldo-keto reductase family 1, member B7 210.7
NM_001037939 Mm.213026 bone gamma carboxyglutamate protein 1 25
NM_011224 Mm.27806 muscle glycogen phosphorylase 24.3
NM_145953 Mm.28301 cystathionase (cystathionine gamma-lyase) 24.3
NM_178405 Mm.207432 ATPase, Na+/K+ transporting, alpha 2 polypeptide 24.2
NM_009943 Mm.43824 cytochrome c oxidase, subunit VI a, polypeptide 2 23.8
NM_009204 Mm.10661 solute carrier family 2 (facilitated glucose transporter), member 4 23.5
NM_011710 Mm.38433 tryptophanyl-tRNA synthetase 23.5
NM_009802 Mm.232523 carbonic anhydrase 6 23.4
NM_172451 Mm.384000 UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 6
23.2
NM_013820 Mm.255848 hexokinase 2 23.2
NM_178405 Mm.207432 ATPase, Na+/K+ transporting, alpha 2 polypeptide 23
NM_019578 Mm.30978 exostoses (multiple)-like 1 22.8
NM_144554 Mm.276018 induced in fatty liver dystrophy 2 22.8
NM_018870 Mm.219627 phosphoglycerate mutase 2 22.6
NM_013703 Mm.4141 very low-density lipoprotein receptor 22.6
NM_009944 Mm.12907 cytochrome c oxidase, subunit VIIa 1 22.6
NM_007504 Mm.35134 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 22.5
NM_013755 Mm.6375 glycogenin 1 22.3
NM_007421 Mm.3440 adenylosuccinate synthetase, muscle 22.2
NM_010514 Mm.3862 insulin-like growth factor 2 22.1
NM_027807 Mm.218910 cullin 5 22.1
NM_009710 Mm.261071 ADP-ribosyltransferase 1 22
NM_016808 Mm.272770 ubiquitin-specific protease 2 22
NM_007710 Mm.2375 creatin kinase (Ckm) 22
NM_016808 Mm.272770 ubiquitin-specific peptidase 2 (Usp2) 21.9
NM_009722 Mm.321755 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 1.9
Neurophysiological Processes
NM_145526 Mm.41252 purinergic receptor P2X, ligand-gated ion channel, 3 25
NM_009109 Mm.226037 ryanodine receptor 1, skeletal muscle 23.25
NM_031173 Mm.41252 calcium channel, voltage-dependent, beta 1 subunit 22.1
NM_008076 Mm.6227 gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 22.1
NM_009604 Mm.2810 cholinergic receptor, nicotinic, gamma polypeptide 22
NM_009497 Mm.28643 vesicle-associated membrane protein 2 21.8
XM_149971 Mm.374440 G protein-coupled receptor, family C, group 5, member C 21.8
NM_009604 Mm.2810 cholinergic receptor, nicotinic, gamma polypeptide 21.7
Transcription and Chromatin Regulation
NM_025282 Mm.24001 myocyte enhancer factor 2C 26.3
NM_013468 Mm.10279 ankyrin repeat domain 1 (cardiac muscle) 24
NM_019738 Mm.18742 nuclear protein 1 (Nupr1) 23
NM_007837 Mm.110220 DNA damage-inducible transcript 3 23
NM_031189 Mm.16528 Myogenina 23
(Continued on next page)
RNA Helicases and Noncoding RNA Control Myogenesis
555Table 1. Continued
Transcription and Chromatin Regulation
NM_009762 Mm.234274 SET and MYND domain containing 1 22.7
NM_024250 Mm.46750 PHD finger protein 10 22.2
NM_009326 Mm.232523 transcription elongation factor A (SII) 1 21.9
Signal Transduction
NM_010200 Mm.7995 fibroblast growth factor 13 22.9
NM_175540 Mm.189270 ectodysplasin A2 isoform receptor 22.4
XM_284144 Mm.6256 frizzled homolog 9 (Drosophila) 22
NM_054071 Mm.35691 fibroblast growth factor receptor-like 1 22
Miscellaneous
NM_019581 Mm.22147 GTP binding protein 2 24.3
NM_013549 Mm.205601 histone 2, H2aa1 24
NM_007836 Mm.72235 growth arrest and DNA damage-inducible 45 alpha 23.7
NM_010174 Mm.22220 fatty acid binding protein 3, muscle and heart 23.6
NM_015786 Mm.193539 histone 1, H1c 23.3
NM_023422 Mm.261676 histone 1, H2bc 23.3
NM_019581 Mm.22147 GTP binding protein 2 23.2
NM_153502 Mm.41421 ankyrin repeat domain 23 22.5
NM_013868 Mm.46181 heat shock protein family, member 7 (cardiovascular) 22.5
NM_133769 Mm.154358 cytoplasmic FMR1 interacting protein 2 22.4
NM_007871 Mm.39292 dynamin 2 22.4
NM_011193 Mm.2534 proline-serine-threonine phosphatase-interacting protein 1 22.4
NM_013712 Mm.46232 integrin beta 1 binding protein 2 22.3
NM_145375 Mm.28887 transmembrane 6 superfamily member 1 22.3
NM_020013 Mm.143736 fibroblast growth factor 21 22
Total RNA was obtained from C2C12 cells cultured in differentiation medium for 36 hr. The nucleotide and UniGene accession numbers are
indicated in the first two columns. Fold reduction indicates the extent of reduction in gene expression observed in shRNA p68/p72 C2C12 cells
compared to control cells.
a Measured by qRT-PCR after 12 hr of differentiation.internal control. The results of these experiments (Fig-
ure 4I) indicate that cells with reduced levels of p68/
p72 failed to appropriately activate the muscle-specific
constructs, including the 4RE-luc, further suggesting
that p68/p72 are transcriptional coactivators of the myo-
genic bHLH proteins in skeletal muscle cells.
SRA transcript levels do not change during differentia-
tion (Figure S1C), but the finding that SRA associates
with and coactivates MyoD prompted us to further eval-
uate its role in muscle gene expression. The SRA tran-
script levels were reduced by transfecting C2C12 cells
with in vitro-transcribed and Dicer-processed SRA RNA
(Figure 5A). Several attempts to lower SRA by using a
retroviral-based shRNA system were unsuccessful. The
difficulties we experienced with the retroviral approach
may be related to the complex secondary structure of
SRA (Lanz et al., 2002) that may prevent access of single
siRNAs to specific regions of the RNA target. Cells trans-
fected with two rounds of Dicer-processed SRA RNAs
were impaired in their ability to differentiate and to acti-
vate transcription of several muscle-specific genes (Fig-
ures 5B–5E). The potential nonspecific, off-target effects
of the small RNAs were controlled by transfecting Dicer-
processed negative control RNAs that did not affect cell
differentiation (Figure 5). Similar, to the results obtained
with p68/p72 interference, expression of MEF2A, pRb,
and follistatin genes was not influenced by SRA (Fig-
ure 5E). These effects are unlikely to be mediated by re-
duced levels of p68 since SRA interference did not affect
p68 expression (Figure 5D). Overall, the results of the
experiments described in this paragraph indicate that
p68/p72 and SRA are required for undifferentiated myo-
blasts to properly mature into terminally differentiatedmyotubes, and that p68/p72 are coregulators of myo-
genic bHLH in skeletal muscle cells. Moreover, they indi-
cate that regulation of a subset of genes activated by
MyoD is not influenced by either p68/72 or SRA.
p68 and p72 Regulate the Assembly of Selected
Members of the Transcriptome and Are Critical
for the Chromatin Remodeling of Muscle
Regulatory Regions
p68/p72 regulate transcription mediated by the nuclear
hormone receptors p53 (Endoh et al., 1999; Watanabe
et al., 2001; Metivier et al., 2003; Bates et al., 2005) and
MyoD (this study), but the mechanisms through which
they influence transcription have not been defined. Since
p68 copurifies with MyoD and is found at chromatin reg-
ulatory regions of actively transcribed muscle-specific
genes, we considered the possibility that p68/p72 may
be involved in the assembly of the muscle transcriptome.
MyoD can access genes in repressive chromatin, ini-
tiate chromatin remodeling, and activate transcription
through recruitment of the ATP-dependent chromatin
remodeling SWI/SNF complex and histone acetyltrans-
ferase p300 and PCAF (Sartorelli and Caretti, 2005;
Tapscott, 2005). Moreover, TBP stabilizes the binding
of MyoD to its DNA binding sites and facilitates the asso-
ciation of TFIIB with the preinitation complex (Heller and
Bengal, 1998). Therefore, we evaluated the presence
of MyoD; p300; the ATPase subunit of the SWI/SNF
complex, Brg-1; TBP; Pol II; and p68 at the MHCIIb and
troponin C promoters by ChIP assay. Immunoprecipita-
tions with nonspecific IgG were carried out as a negative
control. Amplification of the b-globin promoter was em-
ployed as a negative control. Surprisingly, we found
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(A) In vitro-transcribed double-stranded SRA RNA was incubated either in the absence (2) or presence (+) of the Dicer protein and was resolved
on a 1% agarose gel.
(B) C2C12 cells were transfected twice with either a control or Dicer-treated SRA RNA. After the second transfection, cells were grown in differ-
entiation medium for 36 hr. Immunofluorescence was performed with an MHC antibody.
(C) Immonoblot analysis of MHC and tubulin in control and siRNA SRA-transfected C2C12 cells.
(D) RT-PCR analysis of SRA, MCK, MHC, Mbph1 (myosin binding protein 1), p68, and GAPDH transcripts in control and siRNA SRA-transfected
C2C12 cells.
(E) RT-PCR analysis of SRA, MCK, MHC, Mbph1, MEF2A, FS, and Rb transcripts in control and siRNA SRA-transfected C2C12 cells. Error bars
represent standard deviations.that reducing the levels of p68/p72 proteins impaired the
recruitment of Brg-1, TBP, and Pol II without significantly
affecting binding of MyoD and p300 (Figures 6A and 6B).
Consistent with the unperturbed recruitment of p300,
histone H4 acetylation at the MHCIIb and troponin C pro-
moters was not affected in shRNA p68/p72. Expression
of FS and Rb is not regulated by p68/p72, and, accord-
ingly, p68 is not recruited at their regulatory regions (Fig-
ure 4). Consistent with these observations, reducing the
levels of p68/p72 did not affect recruitment of Brg-1,
TBP, Pol II, and p300 at the FS and Rb promoters
(Figure S6A). Since SWI/SNF has been shown to mediate
chromatin remodeling of MyoD-regulated genes (de la
Serna et al., 2001; Simone et al., 2004), we probed the
chromatin structure of the MHCIIb promoter by restric-
tion endonuclease accessibility. The chromatin of the
MHCIIb promoter obtained from shRNA p68/p72 cells
was less accessible to the endonuclease BanI when
compared to that of control cells, indicating that reduced
recruitment of Brg-1 was accompanied by impaired chro-
matin remodeling (Figures 6D and 6E). No differences in
chromatin accessibility were noted in the b-globin gene
(Figure 6D). The protein levels of Brg-1, TBP, and Pol IIare not diminished in cells with reduced levels of p68/
p72 (Figure 6C), and this excludes the possibility that
p68/p72 may directly regulate their expression/stabiliza-
tion. Therefore, we speculated that the mechanism
through which the RNA helicases affect chromatin re-
cruitment of Brg-1, TBP, and Pol II might entail formation
of a protein complex. To directly test this hypothesis,
cells were transfected with a Flag-p68 expression vec-
tor, and cellular extracts were prepared and immunopre-
cipitated with either control IgG or anti-Flag antibody.
Immunoblot analysis with anti-Brg-1, -TBP, or -Pol II
antibodies revealed that Flag-p68 could associate with
endogenous Brg-1, TBP, and Pol II (Figure 6F). To extend
these findings to endogenous proteins, immunoprecipi-
tation experiments were conducted with anti-Brg-1, anti-
TBP, or anti-Pol II antibodies and extract derived from
skeletal muscle cells. Immunoblotting of the precipitated
materials with anti-p68 antibodies indicated that endog-
enous p68 could associate with endogenous Brg-1, TBP,
and Pol II (Figure 6G). Since MyoD interacts with Brg-1
(Simone et al., 2004; de la Serna et al., 2005), we asked
whether p68/p72 may promote and/or stabilize their as-
sociation. Indeed, the interaction of Brg-1 with MyoD
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moter Are Impaired in Cells with Reduced Levels of p68/p72
(A) ChIP assay performed with chromatin derived from C2C12 cells transfected with either control scrambled (C) or p68/p72 siRNAs (i = inter-
fered) and grown in differentiation medium for 36 hr. The antibodies employed are indicated at the top of the panel. For each point, two different
dilutions of the immunoprecipitated DNA were employed. The immunoprecipitated DNA was amplified by PCR with specific primers for the
MHCIIb and fast skeletal troponin C (TnnC2) promoters. The b-globin promoter was amplified as a negative control.
(B) The ChIP assay was performed as described in (A), and DNA amplification was performed by RT-PCR. The fold enrichment was obtained after
correcting for the values observed with the DNA derived from immunoprecipitations performed with nonspecific IgG, which were set as one unit
in each calculation, as described by Caretti et al. (2004). RT-PCR runs were performed with triplicate samples and were repeated with DNA
obtained from three independent experiments. The error bars indicate standard errors of the mean.
(C) Immunoblotting of proteins derived from C2C12 cells transfected with either control scrambled (C) or p68/p72 siRNAs (i) The antibodies
employed are indicated on the left part of the panel.
(D) Nuclei derived from either control or shRNA p68/p72 C2C12 cells were isolated and incubated with BanI for 45 min. The DNA was purified, and
three dilutions (1:30; 1:100, and 1:300) were amplified by PCR by using oligonucleotides flanking the BanI site of the MHCIIb promoter and, as
a control, oligonucleotides amplifying a fragment of the b–globin gene. (Right panel) Schematic representation of the location of the BanI sites in
the MHCIIb and b-globin genes. The numbers refer to the start of transcription at +1.
(E) The chromatin endonuclease accessibility assay was performed as described in (D), and DNA amplification was performed by RT-PCR. The
fold enrichment was derived after normalization with values obtained from the amplification of the b-globin gene. Error bars represent standard
deviations.
(F) 293 T cells were transfected with the Flag-p68 expression vector, and cell extracts were prepared and immunopurified on anti-Flag antibody-
conjugated agarose or control IgG. The immunoprecipitated material was analyzed by immunoblotting with antibodies against Brg-1, TBP, Pol II,
and Flag.
(G) Cell extracts derived from C2C12 cells were immunoprecipitated with antibodies against Brg-1, TBP, Pol II, or control IgG. The immunopre-
cipitated material was immunoblotted with antibodies against p68, Brg-1, TBP, or Pol II.was diminished in extracts derived from C2C12 cells in
which levels of p68/p72 were reduced by RNA interfer-
ence, suggesting that p68/p72 may act as a tether
between MyoD and Brg-1 (Figure S6B). Overall, these
results indicate that p68/p72 direct and/or stabilize chro-
matin recruitment of proteins involved in the formation
of the transcription initiation complex and chromatin
remodeling.Discussion
We have isolated the prototypic p68 (Ford et al., 1988)
and highly related p72 (Lamm et al., 1996) RNA helicases
as proteins associated with MyoD. The SRA was also
found to be complexed with MyoD. To isolate MyoD-
associated polypeptides, we have chosen to express
MyoD in HeLa cells for the following reasons: (1) large
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cells grown in suspension (Nakatani and Ogryzko, 2003),
and (2) the cell cycle-arresting properties of MyoD (Cre-
scenzi et al., 1990) are ineffective in HeLa cells (data not
shown). These characteristics have allowed us to obtain
sufficient nuclear extracts to be subjected to two con-
secutive immunoaffinity purification steps. The associa-
tion of p68/p72 with overexpressed MyoD initially de-
tected in HeLa extracts was confirmed by using cell
extracts derived from skeletal muscle cells, and all the
subsequent experiments—aimed at the functional char-
acterizations of p68/p72 and SRA—were performed in
skeletal muscle cells. Given that only a small fraction
of p68 interacted with MyoD in muscle cells, we were
surprised to observe that SRA efficiently coimmunopre-
cipitated with MyoD. These findings are compatible with
the existence of complexes containing MyoD and SRA,
but not p68. Consistent with a role in regulating muscle
gene expression, p68—despite being expressed at equi-
valent levels in undifferentiated and differentiated mus-
cle cells—was recruited at muscle loci only when these
were transcriptionally active. This observation can be
explained by the ability of p68 to interact with MyoD
and be recruited on the chromatin only when MyoD
binds and activates its targets. Muscle gene expression
and skeletal muscle differentiation were impaired in
cells with reduced levels of either p68/p72 or SRA.
The Noncoding RNA Steroid Receptor Activator
and the RNA Helicases p68 and p72
SRA was originally identified as a noncoding RNA highly
enriched in liver and skeletal muscle and present in dis-
tinct ribonucleoprotein complexes selectively interact-
ing with and activating transcription mediated by steroid
hormone receptors (Lanz et al., 1999). Further studies
indicated that SRA is subjected to both negative and
positive regulations. SRA-mediated steroid receptor
transcription activity could be suppressed by a cofactor,
SHARP (SMRT/HDAC1-associated repressor protein),
whose expression is itself steroid inducible, suggesting
that SHARP may be part of a feedback mechanism to
attenuate hormonal response (Shi et al., 2001). More re-
cently, another corepressor, the small protein SLIRP,
has been demonstrated to bind SRA and to cooperate
with SHARP in inducing repression of nuclear receptor
transactivation in a SRA-dependent manner (Hatchell
et al., 2006). At variance, the pseudouridine synthase
mPus1p, an enzyme that isomerizes uridine to pseu-
douridine in noncoding RNAs, catalyzes pseudouridyla-
tion of SRA in vitro. mPus1p cooperates with SRA to en-
hance not only RAR-dependent transcription, but also
that mediated by other nuclear receptors (Zhao et al.,
2004). While pseudouridylated SRA has been suggested
to assume an ‘‘active’’ conformation, its exact role within
a transcriptional complex has not been yet elucidated.
Our findings indicate that the role of SRA as a transcrip-
tional coactivator is not confined to the regulation of ste-
roid hormone receptors, suggesting a broader involve-
ment of this noncoding RNA in transcriptional control.
We cannot exclude the possibility that SRA, rather than
acting as a noncoding RNA, may encode a small endog-
enous protein. Nonetheless, we do not favor this hypo-
thesis for the following two reasons: (1) our in vitro tran-
scription experiments demonstrating a coactivatory roleof SRA were performed with in vitro-transcribed SRA,
and (2) the transfection experiments showing that
SRA coactivates MyoD were performed with a mouse
SRA cDNA expression vector lacking a start codon.
p68/p72 are members of the DEAD-box family of RNA
helicases, characterized by a stretch of eight conserved
motifs including the Asp-Glu-Ala-Asp (D-E-A-D) se-
quence. These RNA helicases have been highly con-
served through evolution, and members of the DEAD-
box family are found in all species, from bacteria to
humans. In yeast, members of the DEAD-box family are
required for cell growth, and in mammalians they regu-
late several biological processes, including transcrip-
tion, splicing, and translation (Tanner and Linder, 2001).
A relevant function of p68/p72 may be related to their
RNA helicase activity (Tanner and Linder, 2001). How-
ever, the helicase activity of p68 is dispensable to assist
transcription mediated by MyoD (Figure 2) and by
other activators (Endoh et al., 1999; Bates et al., 2005).
Therefore, p68 may have additional functions relevant
for transcriptional regulation that have remained elusive.
Role of p68 and p72 Proteins in Directing
the Assembly of the Transcriptome and
Chromatin Remodeling
Our findings indicate that p68/p72 regulate formation of
a competent transcriptional complex. Reducing the pro-
tein levels of p68/p72 through RNA interference reduced
chromatin recruitment not only of p68, but also of the
TATA binding protein TBP, Pol II, and the brahma-related
gene-1 Brg-1, the catalytic subunit of the ATPase chro-
matin remodelling SWI/SNF complex, without affecting
their protein levels. As a consequence, formation of the
transcription initiation complex at the MHCIIb and tropo-
nin C promoters was impaired (as revealed by reduced
recruitment of Pol II), and nucleosome remodeling was
ineffective (as indicated by inefficient chromatin accessi-
bility to restriction enzymes). We propose a model in
which p68/p72 actively recruit and/or stabilize the chro-
matin interactions of members of the muscle transcrip-
tome by physically interacting with Brg-1, TBP, and
Pol II. p68/p 72 are ubiquitously expressed and regulate
transcription mediated by other activators (Endoh et al.,
1999; Watanabe et al., 2001; Metivier et al., 2003; Bates
et al., 2005), and it is possible that the same steps regu-
lated by p68/p72 during transcriptional activation in
muscle cells may also be affected in other transcriptional
systems. Nonetheless, it is important to note that the
transcriptional requirements for p68/p72 (and SRA) are
not absolute, even within genes regulated by MyoD (Fig-
ures 4 and 5). These findings suggest a specific function
of p68/p72 in regulating discrete gene programs. Finally,
the existence of a functional relationship between p68/
p72 and chromatin remodeling complexes is suggested
by the observation that genes whose expression was
affected by p68/p72, such as MCK, MHC, myogenin,
Tnni2, and MybpH, require Brg-1 (de la Serna et al.,
2005), whereas those not affected by p68/p72, such as
pRb, MEF2A, cyclin D3, Hes6, MyoD, and Chrnb1 (Fig-
ures 4C, 4D, and 4G and http://pepr.cnmcresearch.
org), are either not (pRb, cyclin D3, Hes6, MyoD) or mar-
ginally (MEF2A and Chrnb1) affected by Brg-1 (de la
Serna et al., 2005). The selective recruitment of interact-
ing proteins and functional RNAs at discrete subsets of
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by MyoD to generate temporal and gene-specific activa-
tion (Tapscott, 2005).
Experimental Procedures
Plasmids and Retroviral Constructs
The constructs are described in Supplemental Data.
MyoD-Expressing Cells and Protein Purification
HeLa cells were virally transduced and purified by three rounds of
affinity cell sorting with magnetic beads coated with IL2R antibodies
as described (Nakatani and Ogryzko, 2003). Flag-HA-MyoD was
immunoprecipitated and purified from nuclear extracts of HeLa cells
expressing MyoD as described by Nakatani and Ogryzko (2003).
Mass Spectrometry
Mass spectrometry was performed at the Harvard Microchemistry
Facility (HMF) by microcapillary reverse-phase HPLC nano-electro-
spray tandem mass spectrometry (mLC/MS/MS) on a Finnigan LCQ
DECA quadrupole ion trap mass spectrometer. MS/MS spectra were
correlated with known peptide sequences by using the Sequest
algorithm and programs developed at the HMF.
siRNAs
The pcDNA3-mSRA and the pcDNA-AS-mSRA plasmids were linear-
ized with XhoI and were used to prepare a population of siRNA by
using the Silencer siRNA Cocktail Kit (Dicer) (Ambion) by following
the manufacturer’s instructions. The negative control siRNA cocktail
was prepared from the b-gal gene. Transfection of mSRA and nega-
tive control siRNA was performed as described (Caretti et al., 2004).
C2C12 cells were transfected with a mixture of p68/p72 duplex
Stealth (Invitrogen) siRNA or their corresponding scrambled siRNA
(100 nmol each) (Supplemental Data) by using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions; after
30 hr, cells were allowed to differentiate for 36 hr and were harvested.
Chromatin Immunoprecipitation Assay and Chromatin
Endonuclease Accessibility Assay
The methods are reported in Supplemental Data.
Immunoprecipitation and RT-PCR
The methods are reported in Supplemental Data.
Cell Culture and shRNA
Retroviruses expressing p68/p72-specific short hairpin RNA and
control retroviruses were generated by transient transfection of the
SUPER.Retro.Puro sh p68/p72 or pSUPER.Retro.Puro vectors in
Phoenix cells. The viral supernatants were employed to transduced
C2C12 cells. Cells were selected with 2 mg/ml puromycin and then
cultured in either growth medium (DMEM supplemented with 20%
fetal calf serum, 1% antibiotics) or differentiation medium (DMEM
supplemented with 2% horse serum, 1% antibiotics) for 36 hr.
Transient Transfections
Transient transfections of NIH3T3, control and shRNA p68/p72
C2C12 cells, luciferase, and b-gal assays were performed as previ-
ously described (Caretti et al., 2004).
Expression Profiling
The methods are described in Supplemental Data. Gene lists at each
time point are available at the Public Expression Profiling Resource
(http://pepr.cnmcresearch.org, tissue types ‘‘CELLS’’ project ‘‘VSar-
torelli p68 SMC differentiation’’).
Immunoprecipitation, Immunoblotting,
and Immunofluorescence
The methods are reported in Supplemental Data.
Protein Purification, Chromatin Assembly, and In Vitro
Transcription Assay
Flag-MyoDwE12, Flag-PCAF, His-p300, Flag-p68, and Flag-p72
proteins were expressed in baculovirus-infected Sf-9 cells and affin-ity purified with M2-agarose resin (Sigma) as previously described
(Dilworth et al., 2004). SRA was in vitro transcribed and purified by
using the Mega Script T7 kit (Ambion). Nucleosomal arrays were
generated on the 4R-MCK-pAL3 and pG1 templates by using his-
tones purified from HeLa cells and recombinant NAP-1 and ACF
complex as previously described (Ito et al., 1999). Flag-MyoDwE12
(1 pmol), Flag-PCAF (25 fmol), His-p300 (25 fmol), and Flag-p68,
Flag-p72, and SRA (25 fmol of each) were added to reactions as indi-
cated and incubated with 15 fmol nucleosomal 4R-MCK-pAL3 or
pG1 template in the presence of HeLa nuclear extract (60 mg) and
acetyl CoA (1 mM). RNA recovered from the reactions was subjected
to S1 nuclease analysis as previously described (Dilworth et al.,
2004).
Oligonucleotides
The oligonucleotide sequences are reported in Supplemental Data.
Supplemental Data
Supplemental Data include Supplemental Experimental Proce-
dures, figures, and a table and are available at http://www.
developmentalcell.com/cgi/content/full/11/4/547/DC1/.
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